We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Myriad (MYGN) Up 7.1% Since Last Earnings Report: Can It Continue?
Read MoreHide Full Article
A month has gone by since the last earnings report for Myriad Genetics (MYGN - Free Report) . Shares have added about 7.1% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Myriad due for a pullback? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent drivers for Myriad Genetics, Inc. before we dive into how investors and analysts have reacted as of late.
Myriad Genetics Misses Q1 Earnings Estimates
Myriad Genetics, Inc. reported first-quarter 2026 adjusted loss of 9 cents per share, compared with the Zacks Consensus Estimate of 6 cents. The reported figure came wider than the year-ago period’s loss of 3 cents per share.
Adjusted earnings exclude amortization expenses from acquired intangible assets, equity compensation and real estate optimization. GAAP loss per share came in at 36 cents in the quarter compared with the prior-year quarter’s flat earnings.
MYGN’s Revenues
Total revenues rose 2% year over year to $200.4 million but missed the Zacks Consensus Estimate by 1.09%. Testing volumes remained stable in the quarter.
Detailed Breakdown of MYGN’s Q1 Revenues
The Cancer Care Continuum business delivered $120.2 million in revenues in the first quarter of 2026, up 4% year over year. Within this, hereditary cancer testing revenue increased 5%, driven by a 14% increase in volume. Prolaris testing revenue grew 3% year over year.
The Prenatal Health business revenues dropped 15% year over year to $41.9 million. This was due to a 12% decline in volume decreased, reflecting a difficult prior year comparison as the company continues to engage with customers and address the disruption caused by the 2025 second-quarter implementation of its new order management system.
Meanwhile, the GeneSight test revenues within Mental Health grew 24% year over year, reflecting 7% volume growth, and overall improved reimbursement trends.
MYGN’s Q1 Margin Performance
The gross margin rose 16 basis points (bps) to 68.7% due to a 1.8% increase in the cost of revenues.
Research and development expenses dropped 1.5% year over year to $27.1 million. Sales and marketing expenses rose 6.4% to $74 million in the reported quarter. General and administration expenses were $62.2 million, down 6.5% year over year.
The adjusted operating loss was $25.3 million compared with a loss of $29 million in the year-ago quarter.
MYGN’s Financial Position
Myriad Genetics exited the first quarter of 2026 with cash and cash equivalents of $124.4 million compared with $149.6 million at the end of 2025.
Long-term debt amounted to $120.3 million, compared with $119.9 million at the 2025-end.
The cumulative net cash outflow from operating activities at the end of the reported quarter was $15.7 million compared with an outflow of $16.3 million in the year-ago period.
Myriad Genetics’ 2026 Guidance
Myriad Genetics continues to project full-year 2026 revenues to be $860 - $880 million. The Zacks Consensus Estimate is pegged at $861.9 million.
Full-year adjusted gross margin is expected to be in the 68%-69% range. Adjusted EBITDA is forecasted in the $37-$49 million band.
How Have Estimates Been Moving Since Then?
Investors have witnessed a downward trend in estimates review over the past two months.
The consensus estimate has shifted 11.11% due to these changes.
VGM Scores
Currently, Myriad has a great Growth Score of A, though it is lagging a bit on the Momentum Score front with a B. Charting a somewhat similar path, the stock has a grade of C on the value side, putting it in the middle 20% for value investors.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Myriad has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.
Performance of an Industry Player
Myriad belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Biohaven Ltd. (BHVN - Free Report) , has gained 7.7% over the past month. More than a month has passed since the company reported results for the quarter ended March 2026.
Biohaven Ltd. reported revenues of $0 million in the last reported quarter, representing a year-over-year change of 0%. EPS of -$0.88 for the same period compares with -$2.17 a year ago.
For the current quarter, Biohaven Ltd. is expected to post a loss of $0.77 per share, indicating a change of +60.3% from the year-ago quarter. The Zacks Consensus Estimate has changed +4% over the last 30 days.
Biohaven Ltd. has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of C.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Myriad (MYGN) Up 7.1% Since Last Earnings Report: Can It Continue?
A month has gone by since the last earnings report for Myriad Genetics (MYGN - Free Report) . Shares have added about 7.1% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Myriad due for a pullback? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent drivers for Myriad Genetics, Inc. before we dive into how investors and analysts have reacted as of late.
Myriad Genetics Misses Q1 Earnings Estimates
Myriad Genetics, Inc. reported first-quarter 2026 adjusted loss of 9 cents per share, compared with the Zacks Consensus Estimate of 6 cents. The reported figure came wider than the year-ago period’s loss of 3 cents per share.
Adjusted earnings exclude amortization expenses from acquired intangible assets, equity compensation and real estate optimization. GAAP loss per share came in at 36 cents in the quarter compared with the prior-year quarter’s flat earnings.
MYGN’s Revenues
Total revenues rose 2% year over year to $200.4 million but missed the Zacks Consensus Estimate by 1.09%. Testing volumes remained stable in the quarter.
Detailed Breakdown of MYGN’s Q1 Revenues
The Cancer Care Continuum business delivered $120.2 million in revenues in the first quarter of 2026, up 4% year over year. Within this, hereditary cancer testing revenue increased 5%, driven by a 14% increase in volume. Prolaris testing revenue grew 3% year over year.
The Prenatal Health business revenues dropped 15% year over year to $41.9 million. This was due to a 12% decline in volume decreased, reflecting a difficult prior year comparison as the company continues to engage with customers and address the disruption caused by the 2025 second-quarter implementation of its new order management system.
Meanwhile, the GeneSight test revenues within Mental Health grew 24% year over year, reflecting 7% volume growth, and overall improved reimbursement trends.
MYGN’s Q1 Margin Performance
The gross margin rose 16 basis points (bps) to 68.7% due to a 1.8% increase in the cost of revenues.
Research and development expenses dropped 1.5% year over year to $27.1 million. Sales and marketing expenses rose 6.4% to $74 million in the reported quarter. General and administration expenses were $62.2 million, down 6.5% year over year.
The adjusted operating loss was $25.3 million compared with a loss of $29 million in the year-ago quarter.
MYGN’s Financial Position
Myriad Genetics exited the first quarter of 2026 with cash and cash equivalents of $124.4 million compared with $149.6 million at the end of 2025.
Long-term debt amounted to $120.3 million, compared with $119.9 million at the 2025-end.
The cumulative net cash outflow from operating activities at the end of the reported quarter was $15.7 million compared with an outflow of $16.3 million in the year-ago period.
Myriad Genetics’ 2026 Guidance
Myriad Genetics continues to project full-year 2026 revenues to be $860 - $880 million. The Zacks Consensus Estimate is pegged at $861.9 million.
Full-year adjusted gross margin is expected to be in the 68%-69% range. Adjusted EBITDA is forecasted in the $37-$49 million band.
How Have Estimates Been Moving Since Then?
Investors have witnessed a downward trend in estimates review over the past two months.
The consensus estimate has shifted 11.11% due to these changes.
VGM Scores
Currently, Myriad has a great Growth Score of A, though it is lagging a bit on the Momentum Score front with a B. Charting a somewhat similar path, the stock has a grade of C on the value side, putting it in the middle 20% for value investors.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Myriad has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.
Performance of an Industry Player
Myriad belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Biohaven Ltd. (BHVN - Free Report) , has gained 7.7% over the past month. More than a month has passed since the company reported results for the quarter ended March 2026.
Biohaven Ltd. reported revenues of $0 million in the last reported quarter, representing a year-over-year change of 0%. EPS of -$0.88 for the same period compares with -$2.17 a year ago.
For the current quarter, Biohaven Ltd. is expected to post a loss of $0.77 per share, indicating a change of +60.3% from the year-ago quarter. The Zacks Consensus Estimate has changed +4% over the last 30 days.
Biohaven Ltd. has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of C.